Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Left Ventricular Dysfunction - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Left Ventricular Dysfunction - Pipeline Review, H2 2014', provides an overview of the Left Ventricular Dysfunction's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Left Ventricular Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Left Ventricular Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Left Ventricular Dysfunction Overview 6 Therapeutics Development 7 Pipeline Products for Left Ventricular Dysfunction - Overview 7 Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis 8 Left Ventricular Dysfunction - Therapeutics under Development by Companies 9 Left Ventricular Dysfunction - Therapeutics under Investigation by Universities/Institutes 10 Left Ventricular Dysfunction - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Left Ventricular Dysfunction - Products under Development by Companies 14 Left Ventricular Dysfunction - Products under Investigation by Universities/Institutes 15 Left Ventricular Dysfunction - Companies Involved in Therapeutics Development 16 Acorda Therapeutics, Inc. 16 Amgen Inc. 17 Innopharmax Inc. 18 RedHill Biopharma Ltd. 19 Left Ventricular Dysfunction - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 CAP-1001 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 CAP-1002 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 carvedilol CR - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 carvedilol CR - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 cimaglermin alfa - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CTX-101 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 omecamtiv mecarbil - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule to Target O2 Radical for Left Ventricular Dysfunction and Diabetic Complications - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Left Ventricular Dysfunction - Recent Pipeline Updates 40 Left Ventricular Dysfunction - Dormant Projects 49 Left Ventricular Dysfunction - Discontinued Products 50 Left Ventricular Dysfunction - Product Development Milestones 51 Featured News & Press Releases 51 Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013 51 Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013 52 Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 56 Disclaimer 56
List of Tables Number of Products under Development for Left Ventricular Dysfunction, H2 2014 7 Number of Products under Development for Left Ventricular Dysfunction - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Left Ventricular Dysfunction - Pipeline by Acorda Therapeutics, Inc., H2 2014 16 Left Ventricular Dysfunction - Pipeline by Amgen Inc., H2 2014 17 Left Ventricular Dysfunction - Pipeline by Innopharmax Inc., H2 2014 18 Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd., H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Left Ventricular Dysfunction Therapeutics - Recent Pipeline Updates, H2 2014 40 Left Ventricular Dysfunction - Dormant Projects, H2 2014 49 Left Ventricular Dysfunction - Discontinued Products, H2 2014 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.